MRI-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A NEW PARADIGM.
MR-guided radiotherapy
MR-linac
image-guided radiotherapy
online adaptive radiotherapy
prostate cancer
Journal
Acta clinica Croatica
ISSN: 1333-9451
Titre abrégé: Acta Clin Croat
Pays: Croatia
ID NLM: 9425483
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
22
3
2023
Statut:
ppublish
Résumé
Radiotherapy is one of the key treatment modalities for primary prostate cancer. During the last decade, significant advances were made in radiotherapy technology leading to increasing both physical and biological precision. Being a loco-regional treatment approach, radiotherapy requires accurate target dose deposition while sparing surrounding healthy tissue. Conventional radiotherapy is based on computerized tomography (CT) images both for radiotherapy planning and image-guidance, however, shortcomings of CT as soft tissue imaging tool are well known. Nowadays, our ability to further escalate radiotherapy dose using hypofractionation is limited by uncertainties in CT-based image guidance and verification. Magnetic resonance imaging (MRI) is a well established imaging method for pelvic organs. In prostate cancer specifically, MRI accurately depicts prostate zonal anatomy, rectum, bladder, and pelvic floor structures with previously unseen precision owing to its sharp soft tissue contrast. The advantages of including MRI in the clinical workflow of prostate cancer radiotherapy are multifold. MRI allows for true adaptive radiotherapy to unfold based on daily MRI images taken before, during and after each radiotherapy fraction. It enables accurate dose escalation to the prostate and intraprostatic tumor lesions. Technically, MRI high-strength magnetic field and linear accelerator high energy electromagnetic beams are hardly compatible, and important efforts were made to overcome these technical challenges and integrate MRI and linear accelerator into one single treatment device, called MRI-linac. Different systems are produced by two leading vendors in the field and currently, there are around 100 MRI-linacs worldwide in clinical operations. In this narrative review paper, we discuss historical perspective of image guidance in radiotherapy, basic elements of MRI, current clinical developments in MRI-guided prostate cancer radiotherapy, and challenges associated with the use of MRI-linac in clinical practice.
Identifiants
pubmed: 36938552
doi: 10.20471/acc.2022.61.s3.9
pii: acc-61_supp3-65
pmc: PMC10022406
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
65-70Références
Radiat Oncol. 2019 Jun 3;14(1):92
pubmed: 31167658
J Am Coll Radiol. 2009 Dec;6(12):876-83
pubmed: 19945044
Magn Reson Imaging. 2012 Nov;30(9):1216-23
pubmed: 22770686
Radiat Oncol. 2020 May 5;15(1):93
pubmed: 32370788
Clin Transl Radiat Oncol. 2019 Apr 01;18:60-65
pubmed: 31341977
Clin Transl Radiat Oncol. 2019 Apr 26;18:140-145
pubmed: 31341990
Eur J Cancer. 2019 Nov;122:42-52
pubmed: 31614288
Oncologist. 2010;15(4):338-49
pubmed: 20413639
Nat Rev Clin Oncol. 2012 Dec;9(12):688-99
pubmed: 23165124
J Clin Med. 2022 Mar 16;11(6):
pubmed: 35329988
Clin Transl Radiat Oncol. 2019 Apr 02;18:54-59
pubmed: 31341976
Clin Oncol (R Coll Radiol). 2018 Nov;30(11):720-727
pubmed: 30197095
Br J Radiol. 1999 Jun;72(858):590-7
pubmed: 10560342
Cancer Res. 2009 Jan 15;69(2):383-92
pubmed: 19147546
Med Phys. 2021 May;48(5):e67-e85
pubmed: 33577091
Radiology. 2021 Feb;298(2):248-260
pubmed: 33350894
Strahlenther Onkol. 2020 Aug;196(8):691-698
pubmed: 32002567